Key facts
- Sirius Therapeutics’s last known valuation is $252.5M (May 2025).
- It has raised $214.0M; the latest was IPO in Sep 2025.
- Notable investors include OrbiMed, Hankang Capital, Image Frame Investment, BioTrack Capital, CRISPR Therapeutics — 7 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Sirius Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Sirius Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sirius Therapeutics
Developer and researcher of novel RNAi therapies intended to treat chronic diseases. The company provides research and development of RNAi technology and therapeutics for the management of chronic diseases, providing solutions for physicians and patients to manage cardiovascular diseases.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2022
- Employees
- 36
- Website
- siriusrna.com/
- Ownership
- In IPO Registration
Sirius Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sirius Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sirius Therapeutics in its N-PORT filings yet. We sweep new filings monthly.